The article you cited doesn't say anything about kinase inhibitors. It does help make a case for leronlimab.

Quote:

---

Gene Ontology analysis of differentially expressed genes indicated changes in a number of pathways, including leukocyte activation and pro-inflammatory cytokine secretion. Immune cell dysregulation may therefore be at least partially responsible for the differences in morbidity and mortality during infection with the PB1-UFOΔ or PB1-UFOSYN viruses.

---